Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | GPR183 | P32249 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758044 | 1.00 | AHR (0.58) | AHRKDM4EALDH1A1HPGDCYP2C19 | |
| SCHEMBL10422570 | 0.90 | HDAC2 (0.55) | AHRKDM4EALDH1A1HPGDCYP2C19 | |
| SCHEMBL9805475 | 0.89 | AHR (0.48) | AHRKDM4EALDH1A1HPGDCYP2C19 | |
| SCHEMBL9805486 | 0.89 | AHR (0.48) | AHRKDM4EALDH1A1HPGDCYP2C19 | |
| SCHEMBL1882464 | 0.86 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDCYP2C19RAB9A | |
| SCHEMBL3373054 | 0.86 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDCYP2C19RAB9A | |
| SCHEMBL2577996 | 0.86 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDCYP2C19RAB9A | |
| SCHEMBL391122 | 0.86 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDCYP2C19RAB9A | |
| SCHEMBL9679607 | 0.86 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDCYP2C19RAB9A | |
| SCHEMBL9679616 | 0.86 | ALDH1A1 (0.61) | KDM4EALDH1A1HPGDCYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954683-B1 | 2-(PHENYL OR HETEROCYCLYL)-1H-PHENANTHRO(9,10-D)IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK CANADA INC (CA) | 2016-03-02 | — | — | EP | disclosed |
| EP-1828143-B1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2013-03-20 | — | — | EP | disclosed |
| US-7943649-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2011-05-17 | — | — | US | disclosed |
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | MERCK & CO., INC. | 2009-11-19 | — | — | US | disclosed |
| EP-1828143-A4 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-08-26 | — | — | EP | disclosed |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | MERCK FROSST CANADA LTD. (CA) | 2009-07-30 | — | — | US | disclosed |
| EP-1989187-A4 | 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO (9,10-D) IMIDAZOLES | MERCK FROSST CANADA LTD (CA) | 2009-07-08 | — | — | EP | disclosed |
| US-20090111997-A1 | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals | MERCK SHARP & DOHME CORP. | 2009-04-30 | — | — | US | disclosed |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| EP-2019675-A1 | METHODS FOR TREATING OR PREVENTING NEOPLASIAS | Merck Frosst Canada Ltd. (CA) | 2009-02-04 | — | — | EP | disclosed |
| EP-1828143-A1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007095753-A1 | 2-(PHENYL OR HETEROCYCLIC) - 1H-PHENANTHRO [9,10-D] IMIDAZOLES | MERCK FROSST CANADA LTD. (CA) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007059610-A1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007059611-A1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061849-A2 | METHOD OF GENERATING AMORPHOUS SOLID FOR WATER-INSOLUBLE PHARMACEUTICALS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006063466-A1 | 2-(PHENYL OR HETEROCYCLIC)-1H-PHENANTRHO[9,10-D]IMIDAZOLES AS MPGES-1 INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2006-06-22 | — | — | WO | disclosed |
| EP-0391212-B1 | Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers | BAYER AG (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5136013-A | Polyesters | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-04 | — | — | US | disclosed |
| US-5068300-A | BIFUNCTIONAL STILBENE COMPOUNDS CONTAINING AT LEAST ONE Z-CONFIGURATED STILBENE GROUP, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF POLYMERS | BAYER AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0391212-A2 | Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers | BAYER AG (DE) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286772-A1 | 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles | PTGES, PTGS1, PTGES2 | AHR 78/4885KDM4E 1563/4885ALDH1A1 95/4885 |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | GSTO1, PTGS1, PTGES | AHR 711/4885KDM4E 2418/4885ALDH1A1 78/4885 |
| US-20090111997-A1 | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals | WDR33, POLR2H, NSF | AHR 1506/4885KDM4E 2110/4885ALDH1A1 3974/4885 |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | AHR 167/4885KDM4E 1799/4885ALDH1A1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.